These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 34890803

  • 21. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin.
    Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, White SW, Miller DD, Li W, Li W.
    J Med Chem; 2019 Jul 25; 62(14):6734-6750. PubMed ID: 31251599
    [Abstract] [Full Text] [Related]

  • 22. An update on the recent advances and discovery of novel tubulin colchicine binding inhibitors.
    Weng H, Li J, Zhu H, Carver Wong KF, Zhu Z, Xu J.
    Future Med Chem; 2023 Jan 25; 15(1):73-95. PubMed ID: 36756851
    [Abstract] [Full Text] [Related]

  • 23. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B, Panda D, Gupta S, Banerjee M.
    Med Res Rev; 2008 Jan 25; 28(1):155-83. PubMed ID: 17464966
    [Abstract] [Full Text] [Related]

  • 24. High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design.
    Bueno O, Estévez Gallego J, Martins S, Prota AE, Gago F, Gómez-SanJuan A, Camarasa MJ, Barasoain I, Steinmetz MO, Díaz JF, Pérez-Pérez MJ, Liekens S, Priego EM.
    Sci Rep; 2018 Mar 09; 8(1):4242. PubMed ID: 29523799
    [Abstract] [Full Text] [Related]

  • 25. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
    Li Y, Yang J, Niu L, Hu D, Li H, Chen L, Yu Y, Chen Q.
    FEBS Lett; 2020 Jan 09; 594(1):199-204. PubMed ID: 31369682
    [Abstract] [Full Text] [Related]

  • 26. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.
    Mol Pharmacol; 2019 Jul 09; 96(1):73-89. PubMed ID: 31043459
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin.
    Xian J, Bu F, Wang Y, Long F, Zhang Z, Wu C, Tao Y, Wang T, Wang G.
    Molecules; 2021 Feb 10; 26(4):. PubMed ID: 33579052
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.
    Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R.
    Bioorg Med Chem; 2009 May 15; 17(10):3690-7. PubMed ID: 19398206
    [Abstract] [Full Text] [Related]

  • 32. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, Dalton JT, Miller DD, Li W.
    Cancer Res; 2018 Jan 01; 78(1):265-277. PubMed ID: 29180476
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
    Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD, Li W.
    J Med Chem; 2018 Sep 13; 61(17):7877-7891. PubMed ID: 30122035
    [Abstract] [Full Text] [Related]

  • 35. Structural insight into SSE15206 in complex with tubulin provides a rational design for pyrazolinethioamides as tubulin polymerization inhibitors.
    Ma L, Lei J, Chen H, Huang R, Su T, Feng J, Sun Q.
    Future Med Chem; 2022 Jun 13; 14(11):785-794. PubMed ID: 35506429
    [Abstract] [Full Text] [Related]

  • 36. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
    Mirzaei H, Shokrzadeh M, Modanloo M, Ziar A, Riazi GH, Emami S.
    Bioorg Chem; 2017 Dec 13; 75():86-98. PubMed ID: 28922629
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Interaction of pseudolaric acid B with the colchicine site of tubulin.
    Sarkar T, Nguyen TL, Su ZW, Hao J, Bai R, Gussio R, Qiu SX, Hamel E.
    Biochem Pharmacol; 2012 Aug 15; 84(4):444-50. PubMed ID: 22634405
    [Abstract] [Full Text] [Related]

  • 39. Discrimination of ligands with different flexibilities resulting from the plasticity of the binding site in tubulin.
    Chakraborti S, Chakravarty D, Gupta S, Chatterji BP, Dhar G, Poddar A, Panda D, Chakrabarti P, Ghosh Dastidar S, Bhattacharyya B.
    Biochemistry; 2012 Sep 11; 51(36):7138-48. PubMed ID: 22891709
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.